Ensuring IVDR Compliance for Over 300 Products of a US Based In-Vitro Diagnostics Major

Ensuring IVDR Compliance for Over 300 Products of a US Based In-Vitro Diagnostics Major
As the new In-Vitro Regulations kick in, IVD firms start preparing for the transition to comply with the May 2022 deadline. Thorough technical documentation in compliance with Annex I and Annex II and Annex III is essential to meet the regulations. Cyient helped a major immunodiagnostics company to comply with IVDR for over 300 product lines. This ensured they maintained a market position in the EU region.
Download the Case Study